Lightnews — Scholar-powered news

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 2d

The Clade IIb #mpox 🌍 outbreak exposed major gaps in evidence for antivirals 💊, vaccine equity 💉, and surveillance. This review maps the path toward targeted, evidence-based treatments and prevention✨
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

1 1

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 7d

ED study in Japan: Relaxation of COVID-19 IPC practices led to a surge in virus-related exacerbations of COPD (7.7%→52.5%) & asthma (39.7%→66.7%). Reinforcing viral prevention is key in chronic airway disease care.
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 7d

📊 HIV from injection drug use is climbing (2016–2022).
PrEP uptake in PWID remains critically low.
Call to action: integrate ID + addiction care, expand low-barrier services, implement LA-PrEP, and fight stigma through policy + education.
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

2 3

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 16d

Hospital clinician training transformed care for PWUD w/ severe infections. Post-training: 95% applied harm reduction (vs 55%), 69% discussed safer use (vs 38%).
journals.sagepub.com/doi/full/10....

A descriptive survey evaluating the implementation and outcomes of a training session highlighting concepts in antimicrobial management and harm reduction for hospital-based clinicians treating person...

Background: People who use drugs (PWUD) are at increased risk for severe infections and face many barriers when completing conventional, typically parenteral an...

journals.sagepub.com

2 3

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 24d

East Jerusalem hospital study (2019–2023): CRE in 20.6% of Enterobacterales isolates; blaNDM dominated (82%), blaOXA-48 (13%). Prevalence rising, Klebsiella most common. journals.sagepub.com/doi/full/10....

Prevalence, molecular carbapenemase detection, and antibiotic resistance of carbapenem-resistant Enterobacterales in a tertiary care hospital in East Jerusalem (2019–2023): a retrospective study - Lil...

Background: Carbapenem-resistant Enterobacterales (CRE) are a significant public health threat affecting human health globally. Unfortunately, the incidence of ...

journals.sagepub.com

1 1

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 27d

Despite free HIV care & PrEP in Peru, HIV incidence among youth remains high (13% at age 18; 25% in trans youth <18). Restricting PrEP to 18+ misses a critical window. Peru must expand PrEP to 15–17-year-olds.
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

2 4

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 29d

In CNS neuroimmunological disease, anti-CD20/S1PRM therapies blunt humoral responses even after 4th SARS-CoV-2 vaccine dose or breakthrough infection. Encouragingly, no evidence of intermediate-term neuroinflammation or neural injury post-COVID-19
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

1 1

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Sep 7

Rare case: concurrent Mycobacterium avium & M. kansasii infection in a patient w/ MDS & germline GATA2, on cobimetinib. Suggests profound susceptibility to NTM & therapeutic challenges in this setting.
journals.sagepub.com/doi/10.1177/...

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

1 1

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Sep 7

Real-world fascioliasis data (174 pts, TriNetX 2021–24): common comorbidities, GI symptoms, biliary complications in ~10%, 90-day mortality <6%. Triclabendazole reported in just 6%—access or reporting gap? Prospective studies needed
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

1 1

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Sep 4

UTIs drive huge antimicrobial use worldwide. This editorial highlights innovations—PCR, AMR surveillance, PROMs—to guide sustainable, patient-centred therapy.
journals.sagepub.com/doi/full/10....

journals.sagepub.com

1 2

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Sep 2

🧪 Meta-analysis of 5,399 patients: RA patients show TNF-α levels comparable to those in sepsis.
⚠️ Anti-TNF therapy works in RA but not sepsis → TNF-α unlikely to be central in sepsis biology.
journals.sagepub.com/doi/full/10....

journals.sagepub.com

1 4

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Aug 31

Chikungunya: a strong contender for Disease X.
✔ Key mutations drive rapid spread
✔ Debilitating chronic disease + neonatal risk
✔ Vaccine inequity, no treatment
✔ Climate & travel accelerate reach
Global vigilance is critical.
journals.sagepub.com/doi/full/10....

Chikungunya virus: from genetic adaptation to pandemic risk and prevention - Shoubeho Sadique Shandhi, Suprety Malaker, Mohammad Shahriar, Ramisa Anjum, 2025

Chikungunya virus (CHIKV) has emerged as a serious candidate for “Disease X”—the name for an unknown agent that could cause a global pandemic. This paper search...

journals.sagepub.com

2 4

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Aug 18

🇻🇳 Cross-sectional study of 876 pregnant women in Hanoi: GBS colonization prevalence 19.5%. Independent risk factors: higher education & yellow vaginal discharge. Predominant serotypes: III, V, VI.
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

1 1

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Aug 17

💉 Bloodstream infections from carbapenemase-producing Enterobacterales in acute leukemia carry high mortality (~61%). In a Peruvian cohort, use of ceftazidime–avibactam cut 30-day mortality risk by 70% vs. other therapies (aHR 0.29, 95% CI 0.09–0.92).
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

1 1

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Aug 16

💉 “Tranq” (xylazine) + fentanyl → rising overdoses, devastating necrotic wounds, & systemic infections. This vignette shows why new harm reduction tools like drug-checking are urgently needed.
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

1 2

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Aug 3

In a 6-year retrospective, propensity-matched analysis of 111 patients with invasive candidiasis, anidulafungin and caspofungin showed comparable efficacy (global response 63.3% vs 56.3%, p=0.49) and no difference in 90-day mortality.
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

1 1

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Jul 30

🚨Yellow fever is resurging in the Americas. As of April 2025, over 200 human cases and 85 deaths have been reported—CFR ~40%. The virus is moving beyond its traditional Amazonian stronghold. This isn’t just an outbreak—it's a warning.🧵 journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

2 3

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Jul 21

First reported case of Mycoplasma hominis prosthetic valve endocarditis + endophthalmitis post-renal transplant.
✅ Diagnosed by plasma cfDNA mNGS after culture-negative workup
✅ Managed with surgery + doxy/levo
journals.sagepub.com/doi/full/10....

Mycoplasma hominis prosthetic valve infective endocarditis and endophthalmitis in a renal transplant recipient: a case report - Hutton Brandon, Daniel Montelongo-Jauregui, Neeraja Swaminathan, 2025

Mycoplasma hominis is a rare cause of infective endocarditis, typically reported in immunocompetent patients following valve replacement. We report the first ca...

journals.sagepub.com

3 1

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Jul 21

PVL+ Staph aureus ⚡️ causes severe skin infections. In Calabar 🇳🇬, 12.5% of S. aureus isolates were PVL+, tied to recurrent infections & daycare work 🏫.
journals.sagepub.com/doi/full/10....

Molecular detection of mecA and lukSF-PV in patients with Staphylococcus aureus soft tissue infections in a tertiary hospital setting, Calabar, Nigeria: a cross-sectional study - Christian J. Ide, God...

Background: Panton-Valentine Leukocidin (PVL) is one of the major virulence factors known to be associated with invasive, life-threatening Staphylococcus aureus...

journals.sagepub.com

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Jul 19

🦠 Biofilms fuel #AMR & chronic infections, needing 100–1000x more antibiotics to clear. Phages can disrupt biofilms & fight resistant bacteria but face bacterial defenses. Phage-antimicrobial combos may enhance antibiofilm strategies.
journals.sagepub.com/doi/full/10....

Lytic bacteriophages as alternative to overcoming antibiotic-resistant biofilms formed by clinically significant bacteria - Abdul-Halim Osman, Samuel Darkwah, Fleischer C. N. Kotey, Adwoa Asante-Poku,...

Bacterial infections are a major public health threat, with a substantial global burden of ∼5 million deaths in 2019, of which ∼1.27 million were attributed to ...

journals.sagepub.com

1 1

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Jul 19

UTIs aren’t just “simple infections.” They bring anxiety, frustration, & recurrent misery for many. AMR, delayed dx, & clinician focus only on physical symptoms worsen the burden. We need better dialogue & AMR education for patients.
journals.sagepub.com/doi/full/10....

Understanding patient and healthcare provider perspectives of uncomplicated urinary tract infection: patient journey, disease management, and the impact of antimicrobial resistance - Bhaskar Somani, M...

Uncomplicated urinary tract infections (uUTIs/acute cystitis) carry a substantial physical and psychological burden that negatively impacts patient quality-of-l...

journals.sagepub.com

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Jul 14

In NE India’s Manipur, HCV sero-reactivity quadruples in PLHIV who inject drugs. 40% have genotype 6; phylogenetics link strains to SE Asia.
journals.sagepub.com/doi/full/10....

1 2

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Jul 14

🩺💉 Rising IE in PWID, but Syringe service program use is patchy due to rural gaps & relapse fears.
🏥 Discharge planning = chance to connect PWID to harm reduction for safer futures.
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Jul 10

Group B Strep (GBS) isn't just a neonatal issue—it’s linked to preterm birth, PPROM, UTI, endometritis & maternal sepsis too. 🦠
We need better prevention beyond intrapartum antibiotics. Maternal GBS vaccines may be the path forward.
journals.sagepub.com/doi/full/10....

Understanding GBS infection in pregnancy: exploring adverse maternal and pregnancy outcomes and the prospect of a GBS vaccine - Monica Sosa, Linda O. Eckert, Alisa Kachikis, 2025

Group B streptococcus (GBS) or Streptococcus agalactiae is a beta-hemolytic, Gram-positive coccus that can colonize the genitourinary and gastrointestinal tract...

journals.sagepub.com

1

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · Jul 9

🩺💊 New REPRIEVE data confirm abacavir use increases MACE risk in adults with HIV. In the modern ART era, we should critically rethink abacavir’s role in HIV treatment to align with CV risk reduction goals.
journals.sagepub.com/doi/full/10....

Global “expiration” of abacavir in adults with HIV: a rapid review of safety and efficacy concerns challenging its role in modern ART - David B. Cluck, Daniel B. Chastain, Jacob D. Lines, William R. S...

Emerging evidence from the REPRIEVE study cohort has further clarified the association between abacavir use and cardiovascular risk. This analysis, along with p...

journals.sagepub.com

2